BridgeBio Pharma (BBIO) Raw materials — Quarterly & Annual

Screener

Raw materials at other companies

BioMarin PharmaceuticalsBMRN

$259.35M+117%

ALN

Alnylam PharmaceuticalsALNY

$13.91M-39.2%

Zevra Therapeutics, Inc.ZVRA

$15K-28.6%

Mirum Pharmaceuticals, Inc.MIRM

$2.61M-10.6%

Other financials

Income statement

Revenue$243.7M+120%

Gross profit$228.6M+114%

Operating income-$107.1M+20.3%

Net income-$155.9M+15.2%

EPS (diluted)-$0.78+17.9%

Balance sheet

Cash & equivalents$680.0M-9.5%

Total debt$3.3B+36,912%

Total equity-$2.5B-40.7%

Total assets$1.2B+12.7%

Cash flow

Operating cash flow-$71.1M+11.9%

CapEx$443.0K-25.4%

Free cash flow-$71.5M+12.0%

Valuation

Market cap$16.55B+79.4%

Enterprise value$19.13B+126%

P/S23.2×-15.9×

Profitability

Gross margin94.4%-1.8pp

Operating margin-69.8%-29.9pp

Net margin-98.5%-40.7pp

FCF margin-61.1%-26.8pp

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.2×-4.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.

Filed: Aug 10, 2026, 4:31 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001743881-26-000027

Line item	June 30, 2026	December 31, 2025
Raw materials	$27,853	$14,997
Work in process	16,700	6,104
Finished goods	11,119	6,509
Inventory reserve	(2,830)	(857)
Total inventories	$52,842	$26,753

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's raw materials?: BridgeBio Pharma (BBIO) reported raw materials of $27.85M in Q2 2026.
What does raw materials mean?: Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about BridgeBio Pharma's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk